Jacobio Pharmaceuticals Group Co., Ltd. (OTCMKTS:JBPHF) Short Interest Update
by Sarita Garza · The Markets DailyJacobio Pharmaceuticals Group Co., Ltd. (OTCMKTS:JBPHF – Get Free Report) saw a significant increase in short interest in September. As of September 15th, there was short interest totaling 1,500 shares. Based on an average daily trading volume, of 300 shares, the short-interest ratio is presently 5.0 days.
Jacobio Pharmaceuticals Group Stock Performance
Shares of JBPHF remained flat at $0.72 during trading hours on Monday. The firm’s 50-day moving average is $0.67 and its 200 day moving average is $0.79. Jacobio Pharmaceuticals Group has a 12-month low of $0.60 and a 12-month high of $0.74.
Jacobio Pharmaceuticals Group Company Profile
Jacobio Pharmaceuticals Group is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapies for cancer. The company uses proprietary drug-discovery platforms to develop small-molecule medicines aimed at genetically defined or otherwise difficult-to-treat tumors.
Its pipeline has included JAB-21822, also known as glecirasib, an investigational KRAS G12C inhibitor designed to target cancers driven by KRAS G12C mutations. Jacobio has also developed JAB-3312, an SHP2 inhibitor intended for use in oncology, along with other early-stage programs involving targets such as BET proteins and additional cancer-related pathways.
Jacobio conducts research and clinical-development activities primarily in China, with programs and collaborations extending to international markets, including the United States.